Protocol for Safety, Feasibility, and Efficacy of Using Targeted Transcutaneous Spinal Cord Stimulation to Treat Hypotension During Acute Inpatient Rehabilitation in Individuals With SCI

针对脊髓损伤患者急性住院康复期间低血压的靶向经皮脊髓刺激治疗方案的安全性、可行性和有效性研究

阅读:4

Abstract

BACKGROUND: Transcutaneous spinal cord stimulation (tSCS) has shown evidence of leveraging intact neural circuits to increase blood pressure (BP) in hypotensive people with chronic spinal cord injury (SCI). OBJECTIVES: The primary aim is to determine the safety and feasibility of using tSCS to promote seated systolic BP (SBP) within a target range of 110-130 mm Hg and to mitigate the fall in BP with transition to an upright position in hypotensive participants during acute inpatient rehabilitation (AIR) following SCI. DESIGN/METHODS: Cathode placement on the spine will be randomized among 4 sites: T7/8, T9/10, T11/12, and L1/2. Mapping for other stimulation parameters includes waveform (monophasic, biphasic, pseudo-monophasic), frequency (30, 60, 120 Hz), use of a carrier frequency (0, 10 kHz), and stimulation amplitude (0-100 mA). Each mapping session will consist of 2 sit-up tests, one without stimulation followed by one with stimulation. During the sit-up test with stimulation, intensity will be slowly increased to 30 mA with continuous monitoring of BP, heart rate, pain, and symptoms of orthostatic hypotension (OH) and autonomic dysreflexia (AD). Once 30 mA is reached, brachial BP will be monitored for 5 minutes. If below the target SBP range, stimulation intensity will be increased in increments of 5 to 10 mA until one of the following occurs: (1) SBP is within the target range, (2) stimulation is intolerable, (3) 100 mA is reached, or (4) stimulation is delivered for 30 minutes. Safety and feasibility will be measured by assessing burn frequency, pain level, and symptoms of AD and OH along with scheduling compliance.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。